<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pharmaceuticals-13-00096-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pharmaceuticals-13-00096-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Pharmacology of coronavirus disease (COVID-19) therapies under clinical trials.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adverse Effects</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Contra-Indications</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug–Drug Interactions</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Registered Clinical Trials in COVID-19 </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Specific Antiviral Agents</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral RdRp</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated ALT/AST (reversible); 
     <break/>nephrotoxicity
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-significant</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04330690" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04330690</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04365725" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04365725</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04292899" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04292899</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04292730" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04292730</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252664" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04252664</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04257656" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04257656</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04280705" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04280705</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir/Ritonavir </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral 3-chymotrypsin-like protease</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal, nausea, vomiting, and diarrhea. Pancreatitis, hepatotoxicity, and cardiac conduction abnormalities</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity, co-administration with drugs highly dependent on CYP4503A, and co-administration with potent CYP450 3A inducers</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ritonavir: CYP3A4 inhibitor and substrate; CYP2D6 substrate; CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 inducer. P-glycoprotein substrate; and 1 inducer</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04376814" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04376814</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321174" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04321174</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04307693" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04307693</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04350684" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04350684</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04346147" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04346147</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04261907" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04261907</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04276688</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04330690" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04330690</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Darunavir/Cobicistat</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral 3-chymotrypsin-like protease</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dizziness, sleep disturbances, and altered sensorium. GIT upset, headache, skin rash, asthenia, and redistribution of fat</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cobistat: CYP3A and 2D6 inhibitor; p-glycoprotein and OATP1B1 inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252274" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04252274</uri>
     <break/>
     <uri xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=48992" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/showprojen.aspx?proj=48992</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favipiravir</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral RdRp</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anemia, neutropenia, hyperuricemia, diarrhea, and elevated ALT/AST. </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP2C8 and aldehyde oxidase inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04376814" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04376814</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribavirin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral RdRp</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu-like symptoms, depression, suicide, insomnia, irritability, relapse of drug abuse/overdose, and anemia</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-significant</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04276688</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Umifenovir (arbidol)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits spike protein/ACE2 interaction</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergic reaction, GIT upset, and elevated ALT/AST</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-significant</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04350684" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04350684</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuroaminidase inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea, vomiting, psychiatric effects, and nephrotoxicity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-significant</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04261270" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04261270</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04303299" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04303299</uri>
     <break/>
     <uri xlink:href="http://www.chictr.org.cn/searchprojen.aspx?regno=ChiCTR2000029603&amp;title=&amp;officialname=&amp;subjectid=&amp;secondaryid=&amp;applier=&amp;studyleader=&amp;ethicalcommitteesanction=&amp;sponsor=&amp;studyailment=&amp;studyailmentcode=&amp;studytype=0&amp;studystage=0&amp;studydesign=0&amp;minstudyexecutetime=&amp;maxstudyexecutetime=&amp;recruitmentstatus=0&amp;gender=0&amp;agreetosign=&amp;secsponsor=&amp;regstatus=0&amp;country=&amp;province=&amp;city=&amp;institution=&amp;institutionlevel=&amp;measure=&amp;intercode=&amp;sourceofspends=&amp;createyear=0&amp;isuploadrf=&amp;whetherpublic=&amp;btngo=btn&amp;verifycode=&amp;page=1" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/searchprojen.aspx?regno=ChiCTR2000029603&amp;title=&amp;officialname=&amp;subjectid=&amp;secondaryid=&amp;applier=&amp;studyleader=&amp;ethicalcommitteesanction=&amp;sponsor=&amp;studyailment=&amp;studyailmentcode=&amp;studytype=0&amp;studystage=0&amp;studydesign=0&amp;minstudyexecutetime=&amp;maxstudyexecutetime=&amp;recruitmentstatus=0&amp;gender=0&amp;agreetosign=&amp;secsponsor=&amp;regstatus=0&amp;country=&amp;province=&amp;city=&amp;institution=&amp;institutionlevel=&amp;measure=&amp;intercode=&amp;sourceofspends=&amp;createyear=0&amp;isuploadrf=&amp;whetherpublic=&amp;btngo=btn&amp;verifycode=&amp;page=1</uri>
    </td>
   </tr>
   <tr>
    <td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Non-Specific Antiviral Agents</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous Immunoglobulins</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boosts the antiviral immune response</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild, transient, reversible events such as headaches, chills, or flushing; an increased risk of thrombosis, renal dysfunction, and acute renal failure</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgA deficiency and prior hypersensitivity reactions are not contraindications.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-significant</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04350580" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04350580</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348877" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04348877</uri>
     <break/>(antibody-rich plasma)
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interferons</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boosts the antiviral immune response in the early phase of the disease</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">subcutaneous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GIT upset, urinary urgency, leukopenia, lymphocytopenia, neutropenia, and elevated ALT/AST Inflammation at injection site, ataxia, headache, insomnia, asthenia, and flu-like symptoms </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypersensitivity, pregnancy, current severe depression or suicidal ideation, and liver failure. </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits metabolism of zidovudine</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04350684" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04350684</uri>
     <break/>(IFNβ-1)
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04276688</uri>
     <break/>(IFNβ-1)
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04350671" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04350671</uri>
     <break/>(IFNβ-1)
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04343976" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04343976</uri>
     <break/>(IFN-λ)
    </td>
   </tr>
   <tr>
    <td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Immuno-Modulatory Agents</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baricitinib</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JAK-1 and JAK-2 inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serious infections, malignancies,
     <break/>thrombosis, increased serum, alanine, aminotransferase, and serum aspartate aminotransferase
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of venous thromboembolism active or latent tuberculosis infection, pregnancy and lactation serious acute infections, solid-organ transplant recipient, ALT/AST &gt; 5 × upper limit of normal,
     <break/> absolute neutrophil count &lt; 1 × 10
     <sup>9</sup> cells/L,
     <break/> absolute lymphocyte count &lt; 0.2 × 10
     <sup>9</sup> cells/L,
     <break/> hemoglobin &lt; 8 g/dL,
     <break/> estimated glomerular, and filtration rate (GFR) &lt; 30 mL/min/1.73 m
     <sup>2</sup>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is a substrate of BCRP/ABCG2, CYP3A4 (minor), OAT1/3, and P-glycoprotein/ABCB1. Potentially significant interactions may exist</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04358614" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04358614</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04340232" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04340232</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04346147" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04346147</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04320277" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04320277</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04373044" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04373044</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321993" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04321993</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04345289" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04345289</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ruxolitinib</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JAK1 and JAK2 inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uncontrolled HIV infection,
     <break/> active tuberculosis,
     <break/> chronic kidney disease requiring dialysis,
     <break/> ALT/AST &gt; 5 times the upper limit of normal, and pregnancy or lactation.
     <break/> Known or expected to have allergic reactions to the drug
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Substrate for CYP3A4
     <break/>Potentially significant interactions may exist, requiring dose or frequency adjustment
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348071" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04348071</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359290" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04359290</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355793" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04355793</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04354714" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04354714</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04362137" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04362137</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04377620" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04377620</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04366232" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04366232</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04334044" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04334044</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04374149" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04374149</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04338958" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04338958</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04337359" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04337359</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04331665" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04331665</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04361903" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04361903</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348695" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04348695</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camrelizumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Programmed cell death 1 (PD-1) blocking antibody</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reactive skin capillary hyperplasia, hypothyroidism pneumonia, asthenia, leukopenia, and neutropenia</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnancy or lactation;
     <break/> known or expected to have allergic reactions to the drug;
     <break/> autoimmune diseases;
     <break/> history of organ, bone marrow, or hematopoietic stem cell transplantation;
     <break/> and received radiotherapy and chemotherapy for malignant tumor within six months
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04268537" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04268537</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eculizumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complement Inhibitor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases the risk of meningococcal infections, paroxysmal nocturnal hemoglobinuria hemolytic uremic syndrome, and generalized asthenia </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnancy or lactation, history or unresolved, Neisseria meningitis infection, ongoing sepsis, and the presence or suspicion of active and untreated systemic bacterial infection allergy </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minor drug interactions may exist</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04346797" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04346797</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355494" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04355494</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04288713" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04288713</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meplazumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-CD147 antibody</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">intravenous </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No adverse effects were reported in meplazumab-treated patients.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known or expected to have allergic reactions to the drug</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04275245" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04275245</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tocilizumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interleukin-6 Receptor Antagonist</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients treated with tocilizumab are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known or expected to have allergic reactions to the drug</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It may enhance the immunosuppressive effect of biologic disease-modifying antirheumatic drugs (DMARDs).</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04275245" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04275245</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarilumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interleukin-6 Receptor Antagonist</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated ALT/AST </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known or expected to have allergic reactions to the drug</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It may enhance the immunosuppressive effect of DMARDs.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359901" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04359901</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04357808" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04357808</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04315298" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04315298</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04357860" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04357860</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327388" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04327388</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324073" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04324073</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04345289" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04345289</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04322773" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04322773</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT02735707" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02735707</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bevacizumab</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody against the vascular endothelial growth factor (VEGF)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Some studies only reported hematologic toxicities grades ≥4 and nonhematologic toxicities grades ≥3.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Known or expected to have allergic reactions to the drug</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It may enhance the cardiotoxic effect of anthracyclines and the myelosuppressive effect of myelosuppressive agent </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04344782" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04344782</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04305106" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04305106</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04275414" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04275414</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fingolimod </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sphingosine 1-phosphate receptor modulator</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">headache, QTc prolongation asthenia, stuffy nose, sinus pain, diarrhea, and elevated AST/ALT</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A baseline QTc interval ≥ 500 msec, heart block, CAD, pregnancy, and known hypersensitivity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketoconazole increases the drug level; vaccination may be less effective</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04280588" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04280588</uri>
    </td>
   </tr>
   <tr>
    <td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Other Anti-Infective Agents Repurposed to Treat COVID-19</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine and hydroxychloroquine</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral entry and endocytosis</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QTc prolongation, hypoglycemia, neuropsychiatric effects, and retinopathy</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian patients 
     <break/>Ocular disease
     <break/>Visual disturbance
     <break/>Porphyria
     <break/>Psoriasis 
     <break/>Alcoholism
     <break/>Hepatic disease
     <break/>GIT disease
     <break/>G6PD deficiency
     <break/>Myopathy
     <break/>Neurological disease
     <break/>Hypoglycemia 
     <break/>AV block
     <break/>Bradycardia
     <break/>Cardiomyopathy
     <break/>Celiac disease 
     <break/>Heart failure
     <break/>HIV infection
     <break/>Hyperparathyroidism
     <break/>Hypocalcemia
     <break/>Hypokalemia
     <break/>Hypomagnesemia
     <break/>Hypothyroidism
     <break/>Long QT syndrome
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arsenic trioxide
     <break/>Methotrexate
     <break/>Acetaminophen
     <break/>Iron products
     <break/>Kaolin
     <break/>Niacin
     <break/>Rifampin
     <break/>Isoniazid
     <break/>Antiarrhythmic
     <break/>Anti-depressants
     <break/>Vitamins and herbal products
     <break/>Antacids
     <break/>Insulin and antidiabetic agents
     <break/>Cyclosporin
     <break/>ampicillin
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04362332" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04362332</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04328493" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04328493</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04333628" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04333628</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04331600" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04331600</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04303507" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04303507</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04351191" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04351191</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04323527" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04323527</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04308668" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04308668</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04376814" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04376814</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04330690" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04330690</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal pain, hypotension, mild ECG changes, peripheral and facial edema, transient tachycardia, hyperthermia, insomnia, somnolence, vertigo, pruritus, eosinophilia, leukopenia, elevated ALT/AST, myalgia, blurred vision, and Mazzotti reaction (with onchocerciasis)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypersensitivity to ivermectin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Warfarin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04360356" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04360356</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04351347" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04351347</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04374019" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04374019</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azithromycin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral entry and endocytosis</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QTc prolongation, diarrhea, nausea, and abdominal pain</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypersensitivity to azithromycin, erythromycin, and any macrolides or ketolides
     <break/>History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin
     <break/>Long QT syndrome
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nelfinavir
     <break/>Warfarin
     <break/>Digoxin
     <break/>Colchicine
     <break/>Phenytoin
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359316" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04359316</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04332107" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04332107</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04336332" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04336332</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04341727" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04341727</uri>
    </td>
   </tr>
   <tr>
    <td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Drugs Acting on Host Cell Receptors</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin-converting enzyme inhibitors</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases ACE2 epithelial cell lung expression</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cough
     <break/>Creatinine increased
     <break/>Syncope
     <break/>Hyperkalemia
     <break/>Hypotension 
     <break/>Diarrhea
     <break/>Chest pain 
     <break/>Abdominal pain 
     <break/>Rash 
     <break/>Infection 
     <break/>Asthenia
     <break/>Angina pectoris
     <break/>Dyspnea
     <break/>Pruritus
     <break/>Headache 
     <break/>Dizziness 
     <break/>Increased BUN and serum creatinine
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypersensitivity to ACE inhibitors
     <break/>History of ACE inhibitor-induced angioedema and hereditary or idiopathic angioedema
     <break/>Coadministration of neprilysin inhibitors 
     <break/>with aliskiren in patients with diabetes mellitus or with renal impairment
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salt substitutes with potassium
     <break/>Non-steroidal anti-inflammatory drugs
     <break/>Digoxin (only with captopril)
     <break/>Probenecid (only with captopril)
     <break/>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04366050" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04366050</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355429" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04355429</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04345406" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04345406</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04374695" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04374695</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin receptor blockers</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increases ACE2 epithelial cell lung expression</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dizziness
     <break/>Headache
     <break/>Hyperkalemia.
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bilateral renal artery stenosis</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACEi
     <break/>Aliskiren
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04335123" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04335123</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04311177" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04311177</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04312009" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04312009</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04343001" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04343001</uri>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camostat</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits TMPRSS2 and prevent viral-cell entry </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal liver function tests,
     <break/>Diarrhea
     <break/>Hyperkalemia
     <break/>Itching
     <break/>Jaundice
     <break/>Low blood platelets
     <break/>Liver disorder 
     <break/>GIT discomfort
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnancy (teratogenic)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321096" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04321096</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04353284" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04353284</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04338906" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04338906</uri>
     <break/>
     <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355052" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04355052</uri>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Abbreviations: Abbreviations: ABCB: ATP Binding Cassette Subfamily B Member/ Multidrug Resistance Protein; ACEi: angiotensin converting enzyme inhibitor; ALT: alanine transaminase; AST: aspartate transaminase; AV: atrio-ventricular; BCRP/ABCG2: Breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2); CAD: coronary artery disease; CD: cluster of differentiation; CYP: cytochrome P450; DMARDs: disease modifying antirheumatic drugs; ECG: electrocardiography; G6PD: glucose 6-phosphate dehydrogenase; GIT: gastro-intestinal tract; IFN: interferon; Ig: Immunoglobulin; JAK: Janus kinase; OATP: organic anion transport protein; QTc: corrected QT-interval in the ECG; RdRp: RNA-dependent RNA polymerase enzyme; UGT1A: UDP- glucuronosyltransferase 1.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
